Bellen Chemistry Co., Ltd., a leading CRO/CDMO company in China, recently made another big step forward and announced that the company has successfully completed its C round of financing in 6 weeks, with a total investment of a few hundred million US dollars to support the rapid growth of CRO/CMDO business and to build an integrated service platform for small molecule new drug research and development. This round of financing is led by mother fund of China Merchant and Apricot Capital, co-invested by Sherpa Investment. B round leading investing company, Legend Capital and China Capital, took the opportunity and increased more shares in this round.
China Merchant mother fund is the first market-oriented fund of China Merchant Capital. Since the establishment in 2017, it has been working closely and investing the companies that has strong innovation capabilities in the industry by collaborating with several top fund management teams, and by leveraging the rich industry and financial resources from China Merchants Group. The company is committed to focusing on the areas such as health care, advanced manufacturing, financial technology and upgrading of consumption and servicing.
Apricot Capital is a fund aiming to invest outstanding companies in medical and health industry that are in the early or development stage. Its investment projects cover the fields of biopharmaceuticals, life science and technology, medical devices, medical services and diagnostics. With its comprehensive knowledge and rich investment experience, Apricot Capital devotes itself to promote healthy industrial growth to benefit human race by leveraging its capital strength to integrate the large health industry resources.
Sherpa Investment is a new professional medical investment fund set up in 2018. The core members of the team have worked together for many years and have rich investment experience and outstanding historical achievements in China’s medical and health industry. The team is determined to be the climber behind the climbers, helping the entrepreneurs to reach to the top of their business.
Bellen was founded in 2007, focusing on small molecule design and development, the company is determined to build a first-class integrated service platform in China for small molecule new drug development to support the increasing demands from global customers. With several years of growth, the company has extended its service from CRO to CDMO. In addition to R&D center in Beijing, Bellen has built a pilot plant in Yantai, Shandong Province, and an process R&D center in Shanghai in 2017. To better support customers globally, the company has set up marketing and sales branches in Europe, Canada and United States.
The smooth and fast completion of the financing in this round fully demonstrates the trust and confidence from all professional investors, that Bellen has a clear vision, great growth potential and a highly effective management team. The company will use this round of fund to build a new research and development center in Beijing, new line starts up in Shandong plant and further expansion of process R&D center in Shanghai.
Bellen is a world-wide CRO/CDMO company, committed to provide one-stop chemical service shop to support pharmaceutical customers on small molecule drug discovery and development business, with the service range along the whole drug roadmap from lead generation to the launched products. Bellen’s business scope includes Catalog service, custom-synthesis, process chemistry research and development, and manufacture of intermediates and API. FTE and flexible FTE models are also applied in Bellen to meet the need for supporting the customer’s new drug discovery programs.
For further information please visit: www.bellenchem.com
Tel: +86 10 60400363 Ext. 823